• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Shorla Oncology, Eversana Introduce FDA-Approved Leukemia Treatment


Nelarabine injection to be first Shorla product approved in the US.

Blood picture of chronic lymphocytic leukemia or CLL, analyze by microscope, original magnification. Image Credit: Adobe Stock Images/jarun011

Image Credit: Adobe Stock Images/jarun011

Shorla Oncology, a pharmaceutical company, has officially announced the launch of Nelarabine injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in association with Eversana, an organization that offers commercial services for the life sciences industry. Produced for adults and pediatric patients over the age of one, this is the company’s first medication to be approved in the US.

Reportedly, the new therapy provides patients with an alternative to a product that has historically been in shortage for the treatment of T-cell leukemia, an aggressive blood and bone marrow cancer that progresses quickly.

“Patients are directly affected by therapy shortages. Our team is proud that Nelarabine Injection is now available across the United States for clinicians to prescribe as a new treatment option to help patients, particularly children, in their battle against leukemia,” said Sharon Cunningham, CEO and co-founder of Shorla Oncology. “We look forward to helping educate both the clinical and patient communities on this new therapy.”

Related Videos
Related Content